Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stake Boosted by Nuveen Asset Management LLC

Nuveen Asset Management LLC raised its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 9.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 519,019 shares of the medical device company's stock after purchasing an additional 46,594 shares during the quarter. Nuveen Asset Management LLC owned 0.79% of Tandem Diabetes Care worth $18,695,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in TNDM. Arizona State Retirement System boosted its stake in shares of Tandem Diabetes Care by 1.9% during the 4th quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company's stock worth $683,000 after acquiring an additional 362 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Tandem Diabetes Care by 4.3% during the 4th quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock worth $360,000 after purchasing an additional 409 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Tandem Diabetes Care by 8.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company's stock worth $247,000 after purchasing an additional 525 shares during the period. Assetmark Inc. lifted its stake in shares of Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares during the period. Finally, AlphaQuest LLC increased its holdings in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after buying an additional 541 shares during the last quarter.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock traded up $0.14 during mid-day trading on Thursday, hitting $21.29. The company's stock had a trading volume of 120,881 shares, compared to its average volume of 1,482,526. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock has a market capitalization of $1.42 billion, a P/E ratio of -11.03 and a beta of 1.47. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The stock's fifty day moving average price is $19.43 and its two-hundred day moving average price is $27.27.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. During the same quarter in the previous year, the firm posted ($0.65) earnings per share. The company's revenue for the quarter was up 22.3% on a year-over-year basis. Research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.90% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Morgan Stanley cut shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Citigroup increased their price target on shares of Tandem Diabetes Care from $20.00 to $24.00 and gave the stock a "neutral" rating in a research report on Thursday, May 22nd. Canaccord Genuity Group increased their price objective on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Robert W. Baird dropped their price objective on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. Finally, Mizuho began coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $37.47.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.